Age-related Cognitive Decline, Bipolar Disorder, Cognitive Impairment
Conditions
Brief summary
Age is a major risk factor for the development of cognitive disorders and neurodegenerative pathologies. Cognitive disorders during the phases of bipolar disease are known to exist, and alterations increase significantly after the age of 65. Drug treatments seem to have only a limited effect. A cognitive stimulation program has proven his benefit to patients over 65 with neurodegenerative diseases (Israel, 2004). We propose to evaluate this cognitive stimulation program that we have adapted to bipolar disease.
Detailed description
Bipolar disorders, which belong to the category of mood disorders, are the 6th leading cause of disability in the world. Cognitive disorders are known to exist during the phases of bipolar disease, and alterations increase significantly after the age of 65. Recent studies have shown that attention, memory and executive function impairments are the main causes of cognitive disorders. Residual symptoms have a significant impact on the risk of relapse into bipolar disorder and on quality of life. Cognitive stimulation (CS) is a pedagogical approach based on the idea that cognitive skills contribute to personal development in the same way as psychological and social factors. This study aims at assessing a cognitive stimulation program initially developed for patients with neurodegenerative diseases, and adapted to bipolar disease. This program will be compared to the usual practice consisting in consultation with psychiatrist and sometimes in intervention of home nurses.
Interventions
BEHAVIORALcognitive stimulation
Patients participate in one session per week according to the following schedule: * 2 sensory stimulation sessions: identify sensations, emotions, how to manage them. * 2 sessions on association, verbal fluency, and imagination: language as a tool for expression in the face of illness. * 2 voluntary attention sessions: improve daily attention. * 2 sessions of intellectual structuring: stimulating and maintaining memory, carrying out external activities. * 2 sessions of structuring through language: impact on social life. * 2 sessions stimulating the temporal and spatial landmarks: agenda, daily trips.
Sponsors
Groupe Hospitalier de la Rochelle Ré Aunis
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Pre-Inclusion Criteria: * age \> 65 years old * Diagnosis of bipolar illness for more than 10 years * Euthymic phase * Understands and speaks French * Free, informed and express consent Inclusion Criteria: * Mild to moderate neuro-cognitive impairments (MMS Test : 16 ≤ score \< 26)
Exclusion criteria
* Illiteracy * Patient participating in other therapeutic workshops (e. g. psycho-geriatric day hospital care, etc.) * Persons deprived of their liberty by a judicial or administrative decision * Persons of full age who are subject to a legal protection measure * Persons unable to consent * Persons who are not members of or beneficiaries of a social security scheme * Patient's refusal to participate in the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Score at the Frontal Assessment Battery (FAB) | at 3 months after inclusion | The FAB assesses conceptualization (category responses, such as in what way are a banana and an orange are alike?), lexical fluency, programming or motor series (Luria), sensitivity to interference (conflicting instructions, such as tap twice when I tap once), inhibitory control (Go/No-Go), and environmental autonomy (prehension behavior, such as do not take my hands) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients with a positive difference between the scores on the Functional Activities Questionnaire (QAF) | at inclusion | The QAF allows to quickly assess a patient's functional capacity and to identify a functional decline in the patient with a mild neurocognitive disorder, Alzheimer's disease or other neurocognitive disorder. |
| Score at delayed matching-to-sample (DMS48) | at inclusion | The DMS48 is a test of visual recognition memory test |
| Score at DMS48 | at 3 months after inclusion | The DMS48 is a test of visual recognition memory test |
| Time in minutes at the Trail Making Test A (TMTA) | at inclusion | Evaluation of speed of processing. |
| Time in minutes at the Trail Making Test A | at 3 months after inclusion | Evaluation of speed of processing. |
| Number of errors at Trail Making Test B (TMTB) | at inclusion | Evaluation of mental flexibility |
| Score at FAB | at 6 months after inclusion | Scores between the 3-month and 6-month evaluation will determine whether executive analysis functions have been maintained |
| Score at Montreal Cognitive Assessment (MMS) | at inclusion | Assessment for detecting cognitive impairment |
| Score at the Hamilton Depression Rating Scale | at inclusion | Evaluation of patient thymic state |
| Interference score at the Stroop test | at inclusion | Evaluation of selective attention |
| Number of hospitalization due to relapse | at 6 months after inclusion | hospitalization due to relapse |
| Score at Zarit scale (caregiver) | at inclusion | Identification of suffering or exhaustion, anxiety and/or depressive disorder(s), sleep disorder(s), etc. in the caregiver |
| Score at ISAAC test | at inclusion | Measures fluence |
Countries
France
Contacts
Primary ContactCaroline ALLIX-BEGUEC, Ph.D.
Outcome results
None listed